NCT04076228View on ClinicalTrials.gov

Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients

CompletedOBSERVATIONAL
Enrollment

37

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

January 1, 2020

Study Completion Date

January 1, 2020

Conditions
NSCLC Stage IV
Interventions
DRUG

Pembrolizumab

pembrolizumab is a PD-1 inhibitor. Treatment and follow up will be performed at Kiang Wu Hospital in their clinical oncology center. Clinically pathological related information will be recorded.

Trial Locations (1)

999078

Kiang Wu Hospital, Macao

All Listed Sponsors
lead

Kiang Wu Hospital

OTHER

NCT04076228 - Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients | Biotech Hunter | Biotech Hunter